New News information at Drug Development Technology New and updated information from News listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New News information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Faron commences enrolment in Phase II trial of traumakine to treat MOF in RAAA http://www.drugdevelopment-technology.com/news/newsfaron-commences-enrollment-in-phase-ii-trial-of-traumakine-to-treat-mof-in-raaa-5744523 http://www.drugdevelopment-technology.com/news/newsfaron-commences-enrollment-in-phase-ii-trial-of-traumakine-to-treat-mof-in-raaa-5744523 Finland-based clinical stage biopharmaceutical firm Faron Pharmaceuticals has commenced enrolment in the Phase II INFORAAA clinical trial of traumakine (FP-1201-lyo) to treat patients with multi-organ failure (MOF) in ruptured abdominal aorta aneurys… Tue, 21 Feb 2017 00:00:00 GMT Chi-Med begins Phase II trial of savolitinib to treat PSC in China http://www.drugdevelopment-technology.com/news/newschi-med-begins-phase-ii-trial-of-savolitinib-to-treat-psc-in-china-5744885 http://www.drugdevelopment-technology.com/news/newschi-med-begins-phase-ii-trial-of-savolitinib-to-treat-psc-in-china-5744885 Biopharmaceutical firm Hutchison China MediTech (Chi-Med) has begun a Phase II clinical trial of savolitinib for the treatment of locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China. Tue, 21 Feb 2017 00:00:00 GMT Celgene reports positive top-line results from Phase III trial of ozanimod to treat RMS http://www.drugdevelopment-technology.com/news/newscelgene-reports-positive-top-line-results-from-phase-iii-trial-of-ozanimod-to-treat-rms-5744498 http://www.drugdevelopment-technology.com/news/newscelgene-reports-positive-top-line-results-from-phase-iii-trial-of-ozanimod-to-treat-rms-5744498 US-based biotechnology firm Celgene has reported positive top-line results from the Phase III clinical trial (SUNBEAM) of oral ozanimod for the treatment of patients with relapsing multiple sclerosis (RMS). Tue, 21 Feb 2017 00:00:00 GMT University of Liverpool and AKL collaborate to evaluate APPA for osteoarthritis http://www.drugdevelopment-technology.com/news/newsuniversity-of-liverpool-and-akl-collaborate-to-evaluate-appa-for-osteoarthritis-5743748 http://www.drugdevelopment-technology.com/news/newsuniversity-of-liverpool-and-akl-collaborate-to-evaluate-appa-for-osteoarthritis-5743748 The University of Liverpool has collaborated with pharmaceutical firm AKL Research and Development to evaluate a new drug 'APPA' for the treatment of osteoarthritis. Mon, 20 Feb 2017 00:00:00 GMT AstraZeneca announces positive results from Phase III trial of Lynparza for breast cancer http://www.drugdevelopment-technology.com/news/newsastrazeneca-announces-positive-results-from-phase-iii-trial-of-lynparza-for-breast-cancer-5744013 http://www.drugdevelopment-technology.com/news/newsastrazeneca-announces-positive-results-from-phase-iii-trial-of-lynparza-for-breast-cancer-5744013 Biopharmaceutical firm AstraZeneca has announced positive results from its Phase III clinical trial (OlympiAD) of Lynparza (olaparib) to treat patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Mon, 20 Feb 2017 00:00:00 GMT Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma http://www.drugdevelopment-technology.com/news/newstracon-commences-dosing-in-phase-iii-trial-of-trc105-to-treat-angiosarcoma-5742999 http://www.drugdevelopment-technology.com/news/newstracon-commences-dosing-in-phase-iii-trial-of-trc105-to-treat-angiosarcoma-5742999 US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has commenced dosing in its Phase III trial of TRC105 in combination with Votrient (pazopanib) for the treatment of angiosarcoma. Mon, 20 Feb 2017 00:00:00 GMT Deals this week: Aldeyra Therapeutics, Oncology Venture Sweden, Treos Bio http://www.drugdevelopment-technology.com/news/newsdeals-this-week-aldeyra-therapeutics-inc-oncology-venture-sweden-ab-treos-bio-ltd-5741806 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-aldeyra-therapeutics-inc-oncology-venture-sweden-ab-treos-bio-ltd-5741806 US-based biotechnology company Aldeyra Therapeutics has announced a public offering of shares of its common stock to raise funds required primarily for the continued development of its lead compound, ADX-102, and other product candidates. Fri, 17 Feb 2017 00:00:00 GMT M&As this week: Inhalation Sciences, Quotient Clinical http://www.drugdevelopment-technology.com/news/newsmas-this-week-inhalation-sciences-quotient-clinical-5741746 http://www.drugdevelopment-technology.com/news/newsmas-this-week-inhalation-sciences-quotient-clinical-5741746 Swedish drug development services provider Inhalation Sciences Sweden has been acquired by a consortium comprising Per Gerde, Fredrik Sjovall, and Rasunda Forvaltning. Fri, 17 Feb 2017 00:00:00 GMT Theratechnologies reports comparative PK Data on IM and IV administration of ibalizumab in HIV patients http://www.drugdevelopment-technology.com/news/newstheratechnologies-reports-positive-data-from-tmb-121-trial-of-ibalizumab-in-mdr-hiv-5741777 http://www.drugdevelopment-technology.com/news/newstheratechnologies-reports-positive-data-from-tmb-121-trial-of-ibalizumab-in-mdr-hiv-5741777 Pharmaceutical firm Theratechnologies has announced the pharmacokinetics (PK) and pharmacodynamics (PD) data comparing the intramuscular (IM) with the intravenous (IV) administration of ibalizumab. Fri, 17 Feb 2017 00:00:00 GMT Ardelyx reports positive results from Phase III trial of tenapanor for hyperphosphatemia http://www.drugdevelopment-technology.com/news/newsardelyx-reports-positive-results-from-phase-iii-trial-of-tenapanor-for-hyperphosphatemia-5741794 http://www.drugdevelopment-technology.com/news/newsardelyx-reports-positive-results-from-phase-iii-trial-of-tenapanor-for-hyperphosphatemia-5741794 Ardelyx has reported positive results from the Phase III clinical trial of tenapanor to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. Fri, 17 Feb 2017 00:00:00 GMT Sanofi initiates Phase II trial of GZ/SAR402671 to treat Parkinson’s Disease with GBA gene http://www.drugdevelopment-technology.com/news/newssanofi-initiates-phase-ii-trial-of-gzsar402671-to-treat-parkinsons-with-gba-gene-5740872 http://www.drugdevelopment-technology.com/news/newssanofi-initiates-phase-ii-trial-of-gzsar402671-to-treat-parkinsons-with-gba-gene-5740872 Sanofi's specialist care global business unit Sanofi Genzyme has initiated a Phase II trial of an investigational oral therapy GZ/SAR402671 to treat patients with Parkinson’s disease, who carry a single copy mutation of the glucocerebrosidase (GBA) g… Thu, 16 Feb 2017 00:00:00 GMT Berg begins Phase I/II trial of BPM 31510-IV in patients with glioblastoma multiforme http://www.drugdevelopment-technology.com/news/newsberg-begins-phase-iii-trial-of-bpm-31510-iv-in-patients-with-glioblastoma-multiforme-5741150 http://www.drugdevelopment-technology.com/news/newsberg-begins-phase-iii-trial-of-bpm-31510-iv-in-patients-with-glioblastoma-multiforme-5741150 Biopharmaceutical firm Berg has begun a Phase I/II monotherapy clinical trial of its drug candidate BPM 31510-IV to treat patients with glioblastoma multiforme (GBM). Thu, 16 Feb 2017 00:00:00 GMT Merck reports positive results from Phase III trial of doravirine to treat HIV-1 http://www.drugdevelopment-technology.com/news/newsmerck-reports-positive-results-from-phase-iii-trial-of-doravirine-to-treat-hiv-1-5740855 http://www.drugdevelopment-technology.com/news/newsmerck-reports-positive-results-from-phase-iii-trial-of-doravirine-to-treat-hiv-1-5740855 Merck has reported positive results from a pivotal Phase III clinical trial of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection. Thu, 16 Feb 2017 00:00:00 GMT Chi-Med begins Phase I trial of HMPL-453 in Australia for solid malignancies http://www.drugdevelopment-technology.com/news/newschi-med-begins-phase-i-trial-of-hmpl-453-in-australia-for-solid-malignancies-5739361 http://www.drugdevelopment-technology.com/news/newschi-med-begins-phase-i-trial-of-hmpl-453-in-australia-for-solid-malignancies-5739361 Biopharmaceutical company Hutchison China MediTech (Chi-Med) has begun the first-in-human (FIH) Phase I clinical trial of HMPL-453 to treat patients with advanced or metastatic solid malignancies in Australia. Wed, 15 Feb 2017 00:00:00 GMT Progenics initiates Phase I trial of 1095 to treat metastatic prostate cancer http://www.drugdevelopment-technology.com/news/newsprogenics-initiates-phase-i-trial-of-1095-to-treat-metastatic-prostate-cancer-5740122 http://www.drugdevelopment-technology.com/news/newsprogenics-initiates-phase-i-trial-of-1095-to-treat-metastatic-prostate-cancer-5740122 Progenics Pharmaceuticals has initiated the Phase I trial of PSMA-targeted therapeutic compund 131-I-MIP-1095 (1095) for the treatment of patients with metastatic prostate cancer at Memorial Sloan Kettering Cancer Center. Wed, 15 Feb 2017 00:00:00 GMT Sage Therapeutics reports positive top-line results from Phase II trial of SAGE-217 in MDD http://www.drugdevelopment-technology.com/news/newssage-therapeutics-reports-positive-top-line-results-from-phase-ii-trial-of-sage-217-in-mdd-5739354 http://www.drugdevelopment-technology.com/news/newssage-therapeutics-reports-positive-top-line-results-from-phase-ii-trial-of-sage-217-in-mdd-5739354 Clinical-stage biopharmaceutical company Sage Therapeutics has reported positive top-line results from the Phase II clinical trial of orally administered SAGE-217 to treat patients with major depressive disorder (MDD). Wed, 15 Feb 2017 00:00:00 GMT DelMar Pharma begins dosing in Phase II trial of VAL-083 to treat GBM http://www.drugdevelopment-technology.com/news/newsdelmar-pharma-begins-dosing-in-phase-ii-trial-of-val-083-to-treat-gbm-5739027 http://www.drugdevelopment-technology.com/news/newsdelmar-pharma-begins-dosing-in-phase-ii-trial-of-val-083-to-treat-gbm-5739027 Biopharmaceutical firm DelMar Pharmaceuticals has begun dosing in a Phase II clinical trial of VAL-083 for the treatment of MGMT-unmethylated Avastin (bevacizumab)-naïve recurrent glioblastoma multiforme (GBM). Tue, 14 Feb 2017 00:00:00 GMT Biotron begins Phase II trial of BIT225 to treat HIV-1 http://www.drugdevelopment-technology.com/news/newsbiotron-begins-phase-ii-trial-of-bit225-to-treat-hiv-1-5738430 http://www.drugdevelopment-technology.com/news/newsbiotron-begins-phase-ii-trial-of-bit225-to-treat-hiv-1-5738430 Australian-based Biotron has begun the Phase II clinical trial (BIT225-009) of its anti-viral drug BIT225 to treat patients with human immunodeficiency virus (HIV-1) infection. Tue, 14 Feb 2017 00:00:00 GMT PhytoTech initiates Phase II trial of PTL101 to treat pediatric refractory epilepsy http://www.drugdevelopment-technology.com/news/newsphytotech-initiates-phase-ii-trial-of-ptl101-to-treat-pediatric-refractory-epilepsy-5738415 http://www.drugdevelopment-technology.com/news/newsphytotech-initiates-phase-ii-trial-of-ptl101-to-treat-pediatric-refractory-epilepsy-5738415 Australian-based MMJ PhytoTech's Israeli division PhytoTech Therapeutics has initiated the Health Authorities-approved Phase II clinical trial of PTL101 capsules to treat refractory epilepsy in children. Tue, 14 Feb 2017 00:00:00 GMT Cellceutix initiates main clinical site for Phase IIa trial of Kevetrin in ovarian cancer http://www.drugdevelopment-technology.com/news/newscellceutix-initiates-main-clinical-site-for-phase-iia-trial-of-kevetrin-in-ovarian-cancer-5738022 http://www.drugdevelopment-technology.com/news/newscellceutix-initiates-main-clinical-site-for-phase-iia-trial-of-kevetrin-in-ovarian-cancer-5738022 US-based clinical stage biopharmaceutical firm Cellceutix has initiated its main clinical site at a Texas-based cancer centre to begin the Phase IIa clinical trial (CTIX-KEV-201) of Kevetrin for the treatment of platinum-resistant / refractory ovaria… Mon, 13 Feb 2017 00:00:00 GMT